Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

BACKGROUND: Inhibition of angiogenesis is a novel strategy for the treatment of cancer. We evaluated the safety and efficacy of cediranib, a potent small molecule inhibitor of the vascular endothelial growth factor receptor, in patients with refractory or recurrent small cell lung cancer (SCLC). MET...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2911495/
https://ncbi.nlm.nih.gov/pubmed/20559150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181e2fcb0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk